LANDMARK Trial: a Randomised Controlled Trial of Myval THV
A legfontosabb adatok
- Ki végzi
- Meril Life Sciences Pvt. Ltd.
- Hol
- Banská Bystrica (Szlovákia)A helyszín megnézéseMég 16 másik országban, 53 helyszínen
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 988 fő, tervezett
- Kezdés
- 2020. nov. 4.
- Várható befejezés
- 2033. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Myval THV Series
- Contemporary Valves (Sapien THV Series and Evolut THV Series)
- A regiszteradat frissítve
- 2026. augusztus 17.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with severe aortic valve stenosis that causes symptoms. Aortic valve stenosis is a narrowing of the main heart valve. The trial compares the Myval valve with the Sapien and Evolut valves, placed through a thin tube (TAVI).
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- Severe aortic valve stenosis that causes symptoms, in the person's own (native) valve.
- Korábbi kezelés
- The local Heart Team must judge that the person can have TAVI. The person must be able to receive each of the three study valves.
A részvétel fő kizáró okai
- Not willing to give written consent, or legal heirs object to taking part
- Any condition that the study doctor thinks makes taking part unsafe
A regiszter feltételei, szó szerint
Mind a 5 feltétel megnézéseKevesebb
Ki vehet részt
- Patient ≥18 years of age
- Patient or their legal representative has provided written informed consent as approved by the Institutional Review Board (IRB)/Institutional Ethics Committee (IEC) of the investigational site to participate in the study
- As per local Heart Team assessment, patient is eligible for TAVI and the patient is suitable for implantation with all three study devices
Ki nem vehet részt
- Any condition, which in the Investigator's opinion, would preclude safe participation of patient in the study
- Patients who are not willing to provide informed consent form, or whose legal heirs object to their participation in the study
Helyszínek itt: Szlovákia
Még 16 másik országban, 53 helyszínen
- University hospital Banska Bystrica Námestie Ludvíka Svobodu 1Banská Bystrica, SzlovákiaContact: Dr. Martin HudecRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis.
A teljes eredeti leírásKevesebb
This study will be done in total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves)
The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series)
A vizsgálat 4 csoportja
- Myval THV SeriesA vizsgált kezelés
Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site. This treatment arm will be assigned to 384 / 768 subjects enrolled in a study.
- Contemporary ValvesMár használt kezelés, összehasonlításként
* Sapien THV Series will consist of Sapien 3/Sapien 3 Ultra THVs or any subsequent advanced version commercially available at the study site. * Evolut THV Series will include Evolut R/Evolut PRO THVs or any subsequent advanced version commercially available at the study site. This treatment arm will be assigned to 384 / 768 subjects enrolled in a study.
Kezelés: Contemporary Valves (Sapien THV Series and Evolut THV Series)
- Myval THV Series XL Nested RegistryA vizsgált kezelés
A non-randomised, nested registry of patients with anatomy of native aortic annulus suitable to be implanted with extra-large size of Myval THV series (30.5mm or 32mm) as per Heart Team assessment/Investigator's discretion is designed. The objective of this registry is to assess the safety and effectiveness of extra-large sizes of Myval THV series. Approximately 100 patients will be recruited from approximately 30 participating centres in LANDMARK Trial
Kezelés: Myval THV Series
- Myval THV Series Lead-in SetA vizsgált kezelés
The Lead-in Set aims to ensure investigators adhere to protocol requirements related to the Myval THV Series device, including imaging and procedural guidelines. Investigators should be independent before enrolling study subjects, allowing for valuable feedback for initial safety assessments. Each investigator must conduct at least two non-randomized lead-in cases under the guidance of an evaluation committee. Lead-in subjects will only receive the study device, and if implantation fails, standard care will be provided. These subjects will not be included in primary or secondary endpoint analyses but will undergo descriptive analysis. Unique numbers will be assigned to all lead-in subjects, and the committee will evaluate outcomes and site independence for future trial recruitment.
Kezelés: Myval THV Series
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Multinational, Multicentre, Open-label, Randomised, Non-inferiority Trial to Compare Safety and Effectiveness of Meril's Myval Transcatheter Heart Valve (THV) Series vs. Contemporary Valves (Edwards's Sapien THV Series and Medtronic's Evolut THV Series) in Patients With Severe Symptomatic Native Aortic Valve Stenosis
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- Cardiac Damage and Clinical Outcomes in Symptomatic Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.JACC. Cardiovascular interventions, 2026
- Impact of Early Nonfatal Complications After Transcatheter Aortic Valve Implantation on 1-Year Mortality and Quality of Life: Insights From the LANDMARK Trial.Structural heart : the journal of the Heart Team, 2026
- Comparative 30-day echocardiographic outcomes of Myval vs. Sapien and Evolut THVs: insights from LANDMARK trial.European heart journal. Cardiovascular Imaging, 2026
- 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.Journal of the American College of Cardiology, 2026
- Early outcomes of the novel Myval THV series compared to SAPIEN THV series and Evolut THV series in individuals with severe aortic stenosis.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2025
- LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.Lancet (London, England), 2024
- Quantitative Angiographic Assessment of Aortic Regurgitation after Transcatheter Aortic Valve Implantation among Three Balloon-Expandable Valves.Global heart, 2021
- Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: The LANDMARK trial.American heart journal, 2021
- A regiszteradat frissítve
- 2026. augusztus 17.